Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial

Hepatology Research

Volumn 45, Issue 5, 2015, Pages 514-522

  Otsuji, Kentarou ^a   Takai, Koji ^a   Nishigaki, Yoichi ^b   Shimizu, Shougo ^c   Hayashi, Hideki ^b   Imai, Kenji ^a   Suzuki, Yusuke ^b   Hanai, Tatsunori ^a   Ideta, Takayasu ^a   Miyazaki, Tsuneyuki ^a   Tomita, Eiichi ^b   Shimizu, Masahito ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

^c GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

Author keywords

Cisplatin; Efficacy; Hepatocellular carcinoma; Miriplatin; Outcome; Randomized controlled trial; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CISPLATIN; CREATININE; GELATIN SPONGE; IODINATED POPPYSEED OIL; MIRIPLATIN; SERUM ALBUMIN;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANAPHYLAXIS; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TRANSARTERIAL INFUSION CHEMOTHERAPY; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 84928204618     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12376     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 24 (359): 378-390.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
5. Okusaka T, Kasugai H, Shioyama Y etal. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2009; 51: 1030-1036.
6. Falkson G, Ryan LM, Johnson LA etal. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60: 2141-2145.
7. Sasaki Y, Imaoka S, Kasugai H etal. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60: 1194-1203.
8. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989; 64: 1586-1594.
9. Ikeda M, Maeda S, Shibata J etal. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66: 24-31.
10. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
11. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res 1986; 77: 523-525.
12. Okusaka T, Kasugai H, Ishii H etal. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2012; 30: 2015-2025.
13. Fujiyama S, Shibata J, Maeda S etal. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003; 3 (89): 1614-1619.
14. Oguro S, Hashimoto S, Tanaka T etal. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma. Jpn J Radiol 2012; 30: 735-742.
15. Ueda T, Murata S, Yasui D, Mine T, Kumita S. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. Hepatol Res 2013; 43: 1071-1077.
16. Kudo M, Kubo S, Takayasu K etal. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40: 686-692.
17. Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010; 40 (Suppl 1): 2-144.
18. Ruggeberg JU, Gold MS, Bayas JM etal. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 1 (25): 5675-5684.
19. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
20. Miyayama S, Yamashiro M, Shibata Y etal. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol 2012; 30: 263-270.
21. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs 2011; 22: 277-282.
22. Iwazawa J, Ohue S, Hashimoto N, Mitani T. Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin. Cancer Manage Res 2012; 4: 113-119.
23. Okabe K, Beppu T, Haraoka K etal. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res 2011; 31: 2983-2988.
24. Kasai K, Ushio A, Sawara K etal. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3437-3444.
25. Ueda T, Murata S, Yasui D, Mine T, Kumita S. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. Hepatol Res 2013; 43: 1071-1077.
26. Yamanaka K, Hatano E, Narita M etal. Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2011; 41: 303-309.
27. Sahara S, Kawai N, Sato M etal. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 2010; 28: 362-368.
28. Seko Y, Ikeda K, Kawamura Y etal. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 2013; 43: 942-949.
29. Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc Intervent Radiol 2013; 36: 1023-1029.